Table 1.
Potential targeted biologics against inflammatory pruritus in atopic dermatitis (AD).
| The Targets Based on the Mechanism of AD | ||
|---|---|---|
| Th2 Axis | ||
| IL-4Ra | Duplimumab | Phase II, n = 197, EASI score reduction at 16 weeks: 72% vs. 38% |
| IL-13 | Lebrikizumab | Phase II, n > 200, EASI50: 82.4% vs. 62.3% |
| IL-31 | BMS-981164 | Phase I, NCT01614756 |
| IL-31RA | CIM331 | Phase II, n = 264, pruritis score 50% reduction: 40% vs. 20% |
| Th17 axis | ||
| IL-17 | Secukinumab | Phase II, ongoing (NCT02594098) |
| IL12/23 | Ustekinumab | EASI50 at 16 weeks n = 3 [25] Phase 2: SCORAD50 at 16 weeks: 31% vs. 16% n = 33 [26] |
| IL-22 | ILV-094 | Phase II, ongoing (NCT01941537) |
| Epidermis | ||
| TSLP | AMG157 | Phase I, RCDB, n = 157 (NCT00757042) |
| TSLPR | MK8226 | Phase I, completed, n = 40 (NCT01096160) |
IL, Interleukin; EASI, Eczema Area and Severity Index; TSLP, Thymic stromal lymphopoietin; TSLPR, Thymic stromal lymphopoietin receptor; SCORAD, Severity Scoring of Atopic dermatitis Index.